5FU-induced specific activation of CD8+ T cells.

Slides:

Advertisements

Similar presentations

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,

Advertisements

Foxp3 induction dependent on cell cycle progression in vitro.

Resveratrol modulates DSS-induced neutrophils during colitis.

Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of.

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Triggering PD-1 in B cells suppresses tumor-specific immunity and promotes disease progression. Triggering PD-1 in B cells suppresses tumor-specific immunity.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Functions of myeloid cells.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

2aG4 directly induces monocytic MDSCs to differentiate into dendritic cells and macrophages by binding to phosphatidylserine on their cell surface. 2aG4.

PD-1–PD-L1 axis is highly expressed and is not IFNγ-dependent in a subcutaneous murine model of PDA. A, experimental design for establishment of subcutaneous.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

IFNα Induces MDSC Maturation and Loss of Suppressive Function

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

A: Chemical structure of pterosin A

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

CT-26 colon cancer induces the recruitment of protumor mast cells and the accumulation of MDSCs. CT-26 colon carcinoma cells (2 × 105) were injected s.c.

Interacting MDSCs and mast cells (MC) in human colon carcinoma and in the colon of AOM/DSS-induced tumor-bearing mice. Interacting MDSCs and mast cells.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

Cytotoxicity of p5399–107-induced CTL cells.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Butyrate inhibits IFN-γ-induced STAT1 DNA binding.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

TILs upregulate CD137 in an HIF-1α–dependent fashion.

Influenza vaccine enhances NK cell function through IFN-α.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Circulating leukocytes do not efficiently infiltrate advanced solid tumors in IL-15/IL-15Rα complex–treated RIP1-Tag2 mice. Circulating leukocytes do not.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Anti-SEMA4D antibody regulates immune-cell infiltration and inhibits growth of Tubo.A5 orthotopic mammary carcinoma. Anti-SEMA4D antibody regulates immune-cell.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Pdcd4 expression inhibits AP-1 transactivation.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

PDL192 and inhibit the growth of xenograft tumors.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid cells. In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo. Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Presentation transcript:

5FU-induced specific activation of CD8+ T cells. 5FU-induced specific activation of CD8+ T cells. A, EL4 tumor-bearing mice were treated with 5FU (or NaCl for controls; 50 mg/kg body weight) and injected (when indicated) with 5 × 106 MDSC isolated from the spleen of tumor-bearing mice. Tumor-infiltrating leukocytes isolated 5 d after 5FU treatment were stimulated with immobilized anti-CD3 alone, anti-CD3 plus killed EL4 cells, or anti-CD3 plus anti-CD28 for 12 h. IFN-γ production in tumor-infiltrating T CD8 (left) or T CD4 (right) lymphocytes, respectively. B, representative FACS showing the effect of 5FU treatment on IFN-γ production by CD8+ T lymphocytes from EL4 tumor infiltrate and its modulation by passive transfer of MDSC. The experiments were performed thrice with identical results (*, P < 0.05). Julie Vincent et al. Cancer Res 2010;70:3052-3061 ©2010 by American Association for Cancer Research